CCL
Carnival Corporation & plc
CCL has the edge over TSLA overall, supported by stronger valuation and stronger fundamentals.
TSLA
Tesla, Inc.
TSLA's outlook is improving, though it still trails on the overall score.
CCL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Under pressure |
CCL's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
TSLA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Strong |
TSLA's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is under pressure.
CCL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 10x | $24.05 | -18% |
| Forward | 12x | $29.34 | — |
| Current | 13x | $29.34 | — |
| Fair | 14x | $32.52 | +11% |
| Expensive | 21x | $48.32 | +65% |
Historical ranges are pointers, not guarantees.
CCL has the edge over TSLA in the historical PE scenario, which offers more potential upside but is not a forecast.
TSLA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 60x | $54.70 | -86% |
| Fair | 174x | $158 | -60% |
| Forward | 196x | $397 | — |
| Expensive | 415x | $378 | -4.9% |
| Current | 437x | $397 | — |
Historical ranges are pointers, not guarantees.
TSLA's PE is in its expensive range at 437x. If earnings grow as analysts expect, today's price would be 196x next year's earnings, in its fair range.
CCL Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect CCL's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
TSLA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for TSLA, with profitability holding steady. However, they disagree widely on these estimates.
CCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.39 | +3.3% |
| Q3 2026 | $2.31 | +17% |
| Q2 2026 | $2.24 | +18% |
| Q1 2026 | $2.27 | +46% |
| Q4 2025 | $2.02 | +40% |
| Q3 2025 | $1.97 | +67% |
| Q2 2025 | $1.90 | +168% |
| Q1 2025 | $1.55 | +384% |
| Q4 2024 | $1.44 | +$1.50 |
CCL has the edge over TSLA on earnings, with more consistent year-over-year improvement.
TSLA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.03 | +123% |
| Q3 2026 | $0.91 | -39% |
| Q2 2026 | $1.08 | -38% |
| Q1 2026 | $1.09 | -40% |
| Q4 2025 | $1.08 | -47% |
| Q3 2025 | $1.50 | -59% |
| Q2 2025 | $1.73 | -51% |
| Q1 2025 | $1.82 | -53% |
| Q4 2024 | $2.04 | -53% |
TSLA's earnings per share have fallen from their peak: $0.91 over the past year, against $4.30 in late 2023.
CCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.4B | +3.5% |
| Q2 2026 | $6.7B | +5.3% |
| Q1 2026 | $6.2B | +6.1% |
| Q4 2025 | $6.3B | +6.6% |
| Q3 2025 | $8.2B | +3.3% |
| Q2 2025 | $6.3B | +9.5% |
| Q1 2025 | $5.8B | +7.5% |
| Q4 2024 | $5.9B | +10% |
CCL has the edge over TSLA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 26% | -1.5 points |
| Q2 2026 | 13% | -2 points |
| Q1 2026 | 9.8% | +0.5 points |
| Q4 2025 | 12% | +2.2 points |
| Q3 2025 | 28% | +0.3 points |
| Q2 2025 | 15% | +5.1 points |
| Q1 2025 | 9.3% | +4.2 points |
| Q4 2024 | 9.4% | +2.3 points |
CCL has the edge over TSLA on profitability, with a higher operating margin.
TSLA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $28B | -0.2% |
| Q2 2026 | $28.2B | +26% |
| Q1 2026 | $22.4B | +16% |
| Q4 2025 | $24.9B | -3.1% |
| Q3 2025 | $28.1B | +12% |
| Q2 2025 | $22.5B | -12% |
| Q1 2025 | $19.3B | -9.2% |
| Q4 2024 | $25.7B | +2.1% |
TSLA's revenue has picked up after two years of holding roughly level: $28B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.6% | -3.2 points |
| Q2 2026 | 1.4% | -2.7 points |
| Q1 2026 | 4.2% | +2.1 points |
| Q4 2025 | 5.7% | -0.5 points |
| Q3 2025 | 5.8% | -5 points |
| Q2 2025 | 4.1% | -2.2 points |
| Q1 2025 | 2.1% | -3.4 points |
| Q4 2024 | 6.2% | -2 points |
TSLA's operating margin was 2.6% last quarter, down 3.2 points from the same quarter a year ago, near the bottom of its range since 2019.
CCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $712M | -3.3% |
| Q2 2026 | $1.8B | +14% |
| Q1 2026 | $697M | +119% |
| Q4 2025 | $12M | -96% |
| Q3 2025 | $736M | +17% |
| Q2 2025 | $1.5B | +114% |
| Q1 2025 | $318M | +$688M |
| Q4 2024 | $319M | +29% |
CCL has the edge over TSLA on cash flow, with more consistent year-over-year improvement.
TSLA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5B | -62% |
| Q2 2026 | -$1.1B | -848% |
| Q1 2026 | $1.4B | +117% |
| Q4 2025 | $1.4B | -30% |
| Q3 2025 | $4B | +46% |
| Q2 2025 | $146M | -89% |
| Q1 2025 | $664M | +$3.2B |
| Q4 2024 | $2B | -1.6% |
TSLA still generates free cash flow, though less than at its 2025 peak: $3.3B over the past year.
CCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.4% | -20M shares |
| 1 year | -2.4% | -34M shares |
| 3 years | -2% | -28M shares |
| 5 years | +21% | +236M shares |
| Available history | +100% | +684M shares |
CCL has the edge over TSLA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $548M |
| Q4 2021 | $94M |
| Q3 2021 | $94M |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
TSLA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1M shares |
| 1 year | +0.4% | +15M shares |
| 3 years | +1.4% | +48M shares |
| 5 years | +5.1% | +172M shares |
| Available history | +33% | +886M shares |
TSLA has 3.5B diluted shares, about the same as a year ago.
CCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.1x | Elevated |
| Q2 2026 | 3.1x | Elevated |
| Q1 2026 | 3.2x | Elevated |
| Q4 2025 | 3.4x | Elevated |
| Q3 2025 | 3.5x | Elevated |
| Q2 2025 | 3.7x | Elevated |
| Q1 2025 | 4.1x | High |
| Q4 2024 | 4.3x | High |
CCL's net debt is about 3.1 years of its operating earnings (EBITDA), down from 3.5 years a year ago.
TSLA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.8x | Net Cash |
| Q1 2026 | -0.9x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -1.4x | Net Cash |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.1x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
TSLA has the edge over CCL on leverage, with a lower net debt burden relative to earnings.
CCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.6 | Neutral |
| Stochastic | 80.8 | Overbought |
CCL's weekly RSI is 59 (neutral) and its Stochastic is 81 (overbought).
TSLA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.3 | Neutral |
| Stochastic | 72.6 | Neutral |
TSLA's weekly RSI is 54 (neutral) and its Stochastic is 73 (neutral).
CCL PE vs Consumer Cyclical Sector
| Metric | CCL | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 18x | 30% below |
| PE % | 39 | 47 | 8 pts below |
CCL has the edge over TSLA on valuation relative to its sector.
TSLA PE vs Consumer Cyclical Sector
| Metric | TSLA | Sector median | Relative |
|---|---|---|---|
| PE | 437x | 18x | 2,324% above |
| PE % | 84 | 47 | 37 pts above |
TSLA is trading at 437x earnings, a 2324% premium to the Consumer Cyclical sector's median of 18x.
CCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.8 | 9.6% above |
| 20 week MA | $26.3 | 12% above |
| 50 week MA | $27.5 | 6.6% above |
| 100 week MA | $26.6 | 11% above |
| 200 week MA | $21.1 | 39% above |
CCL is in an uptrend: it's above all five of its weekly moving averages, and 39% above its 200-week average.
TSLA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $376.0 | 5.7% above |
| 20 week MA | $364.0 | 9.2% above |
| 50 week MA | $393.6 | 1% above |
| 100 week MA | $372.1 | 6.8% above |
| 200 week MA | $296.9 | 34% above |
TSLA is in an uptrend: it's above all five of its weekly moving averages, and 34% above its 200-week average.
CCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.3 | $20.8 | -59% |
| 2021 | $20.8 | $21.2 | +1.7% |
| 2022 | $21.2 | $7.81 | -63% |
| 2023 | $7.81 | $18.5 | +137% |
| 2024 | $18.5 | $25.1 | +35% |
| 2025 | $25.1 | $30.7 | +22% |
| 2026 YTD | $30.7 | $29.3 | -4.4% |
CCL has the edge over TSLA on returns for 2026, with the stronger performance.
TSLA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.7 | $220.6 | +669% |
| 2021 | $220.6 | $355.7 | +61% |
| 2022 | $355.7 | $123.2 | -65% |
| 2023 | $123.2 | $248.5 | +102% |
| 2024 | $248.5 | $431.7 | +74% |
| 2025 | $431.7 | $475.2 | +10% |
| 2026 YTD | $475.2 | $397.5 | -16% |
TSLA's yearly returns have swung widely, from +669% in 2020 to −65% in 2022. It's down 16% so far in 2026.